title: Influence of acute bupropion pre-treatment on the effects of intranasal cocaine.
abstract: OBJECTIVE
  The aim of this experiment was to determine the influence of acute bupropion pre-treatment on subject-rated effects and choice of intranasal cocaine versus money.
  
  
  METHODS
  A randomized, within-subject, placebo-controlled, double-blind experiment.
  
  
  METHODS
  An out-patient research unit.
  
  
  METHODS
  Eight cocaine-using adults.
  
  
  METHODS
  Subjects completed nine experimental sessions in which they were pre-treated with 0, 100 or 200 mg oral immediate release bupropion. Ninety minutes later they sampled an intranasal cocaine dose [4 (placebo), 15 or 45 mg] and made six choices between that dose and an alternative reinforcer (US$0.25), available on independent, concurrent progressive ratio schedules. Subjects also completed a battery of subject-rated, performance and physiological measures following the sample doses of cocaine.
  
  
  RESULTS
  After 0 mg bupropion, the high dose of cocaine (45 mg) was chosen five of six times on average compared to 2.25 of six choices for placebo cocaine (4 mg) (P < 0.05). Active bupropion reduced choice of 45 mg cocaine to 3.13 (100 mg) or 4.00 (200 mg) out of six drug choices on average. Bupropion also consistently enhanced positive subject-rated effects of cocaine (e.g. good effects; willing to take again) while having no effects of its own.
  
  
  CONCLUSIONS
  The atypical antidepressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug.
authors.affiliation: Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 40536-0086, USA. william.stoops@uky.edu
authors.forename: William W
authors.initials: WW
authors.lastname: Stoops
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Lile
authors.forename: Paul E A
authors.initials: PE
authors.lastname: Glaser
authors.forename: Lon R
authors.initials: LR
authors.lastname: Hays
authors.forename: Craig R
authors.initials: CR
authors.lastname: Rush
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000494:pharmacology*; D016642:Bupropion / Q000008:administration & dosage / Q000494:pharmacology*; D002755:Choice Behavior / Q000187:drug effects*; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000523:psychology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D012201:Reward
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion; D003042:Cocaine